Non-steroidal anti-inflammatory drugs in the alleviation of primary dysmenorrhoeic pain
Date
2009-03-13T07:56:12Z
Authors
Avidon, Ingrid
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
The cramping, and often debilitating, pain which women of child-bearing age experience in
the lower abdomen just before, or during, menstruation, in the absence of any pelvic
pathology, is called primary dysmenorrhoea. The aetiology of dysmenorrhoea is not fully
understood and the condition is often poorly treated. The aim of my thesis is to contribute
knowledge to the assessment and treatment of dysmenorrhoea, as well as objective
measurement of the impact of dysmenorrhoea on physical activity and functional performance.
I completed three separate studies, on three different groups of healthy young women with a
history of moderate-to-severe primary dysmenorrhoea. I used the McGill Pain Questionnaire
(MPQ) and the visual analogue scale (VAS), as indices of pain intensity, to assess the efficacy
of three cycloxygenase (COX) inhibitors, covering a spectrum of COX-2 selectivity, in the
treatment of dysmenorrhoea. The pain response index (PRI) and present pain index (PPI),
calculated from the MPQ, and the VAS, were highly correlated as measures of intensity of
dysmenorrhoeic pain. The COX-2 specific inhibitor rofecoxib, and the non-selective COX
inhibitor diclofenac potassium, significantly decreased the duration of dysmenorrhoeic pain,
compared to placebo and compared to meloxicam, a COX-2 selective inhibitor, and were
equally effective in relieving menstrual pain.
Women with dysmenorrhoea subjectively report decreased physical activity, but no studies have attempted to quantify the decrease in exercise performance, or functional ability resulting
from dysmenorrhoea, in a standardized laboratory protocol when women perform structured
physical activity. Furthermore, no method or tool has been described which measures the the
effect of dysmenorrhoea on the activity of daily life. I assessed whether an activity data logger
(actigraphy), worn on the hip, was able to detect, and quantify, pain-reduced physical activity
levels in women with dysmenorrhoea going about their daily lives. In the laboratory protocol I
showed that moderate-to-severe dysmenorrhoea, but not the act of menstruation without pain,
decreased the women’s ability to bend over and stretch upwards, and to perform exercise that
required the use of their lower limb muscles. Administration of diclofenac potassium
attenuated dysmenorrhoea and restored exercise performance and functional ability to levels
attained when the women were in a pain-free phase of the menstrual cycle. I showed that
activity data loggers, worn on the hip of each woman, were able to detect and quantify painreduced
activity of daily life. Moderate-to-severe menstrual pain, but not menstruation itself,
decreased the women’s physical activity, as measured by the data loggers, to about two-thirds
of the activity measured when they were in a pain-free phase of the menstrual cycle In conclusion, I have added further knowledge to the assessment and treatment of
dysmenorrhoea. The VAS and the MPQ, incorporating the PRI and PPI, are interchangeable
indices of intensity of dysmenorrhoea and, depending on the educational status of the cohort,
any one of the indices is suitable for assessment of intensity of pain. Rofecoxib and diclofenac
potassium, two cycloxygenase inhibitors with differing COX-2 specificity, are excellent
pharmacological therapies for the treatment of dysmenorrhoea. Objective assessment of
physical activity, via activity data loggers, is a potentially useful tool to investigate the effects
of dysmenorrhoea on structured physical activity and the activity of daily life, and for
measuring pain-related debilitation and its management.